

Patient Journey

Approccio personalizzato al
paziente e esperienze a
confronto:
Epatocarcinoma e
Colangiocarcinoma

01 Febbraio 2024

VERONA
CROWNE PLAZA
Via Belgio, 16

AIGOM
ASSOCIAZIONE ITALIANA
GRUPPI ONCOLOGICI MULTIDISCIPLINARI

LA GESTIONE DEL PAZIENTE CON COLANGIOCARCINOMA ALL'INTERNO DI UN GRUPPO ONCOLOGICO MULTIDISCIPLINARE: UN CASO CLINICO

Prof Enrico Gringeri, Dott. Andrea Marchini

Chirurgia Generale 2
Azienda-Ospedale-Università di Padova
Direttore Prof. Umberto Cillo



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024

1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Z.F., male, 52 y.o.

- Healthy man, no chronic diseases, no allergies
- **01/2021 itching, jaundice** (bilirubin total/direct 14.7/10.8 mg/dL), **hyperchromic urines, hypochromic stools**
- Admission Gastroenterology ward (Brescia)
- **11/01/2021 T-A CT scan with cm:** enlargement of left bile duct (11mm) and slightly less of the right one, sustained by a **2cmx2 cm mass at the confluence of the common ducts**. Excluded gallbladder. **Hilar lymphadenopathy max 17mm.**
- **12/01/2021 MRI with cm:** confirmation of 22x20mm mass involving the R and L hepatic ducts and the confluence of the 2nd order right branches (accessories?) for S4b and S2. Right and left artery non involved



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024



1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Z.F., male, 52 y.o.

12/01/2021 MRI with cm



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024

1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Z.F., male, 52 y.o.

- 15/01/21 Oncological markers : CEA <2ug/L, Ca 19.9 13 U/mL, AFP 2.5 ug/L
- 08/02/21 ERCP: hilar stenosis -> brushing (atypical epithelial cells, suspicious of cancer)
- 02/02/2021 PET-RMN hypermetabolism of the mass SUV max 5.5



pCCA

Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024

1222-2022
800
ANNI



VERONA

UNIVERSITÀ
DEGLI STUDI
DI PADOVA

pCCA PDTA - Padova

Mappa 1

Sospetto Colangiocarcinoma perilare (extraepatico)



GEM-CIS
 11.7 m survival

OS
 70% at 10 years

Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
 Epatocarcinoma e Colangiocarcinoma



pCCA PDTA - Padova



ALIBERTI CAMILLO
ANGELI PAOLO
BASSI NICOLO'
BURRA PATRIZIA
CILLO UMBERTO
CRIVELLARI GINO
DEI TOS ANGELO PAOLO
D'ONOFRIO MIRKO
FARINATI FABIO
GAGLIARDI GIUSEPPE
GION MASSIMO

✓ PDTA Epatobiliare



Coordinatori: Umberto Cillo, Alfredo Guglielmi, Nicolò Bassi, Vittorina Zagonel

GRINGERI ENRICO

GUGLIELMI ALFREDO

LONARDI SARA

MANEA KATIA

MASSANI MARCO

MAZZAROTTO RENZO

MELISI DAVIDE

MESCOLI CLAUDIA

MORABITO ALBERTO

MORANA GIOVANNI

PALLINI PAOLO

PASTORELLI DAVIDE

Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

Clinical management and Mayo protocol enrollment

- 12/01/2021 left external PTBD
- 27/01/2021 right external PTBD

02/03/2021-22/03/2021: CT-RT, 12 cycles

RESTADIATION

30/04/2021 CT scan: SD. Exclusion of S7, part of S8 and S1 biliary tree

- Cholangitis, 07/05/2021 right external PTBD (confluence S7-S8 and S1)
- 14/05/21 PET-RM involvement of all the hepatic hllum; 91x43mm mass infiltrating both lobes. Reduction of SUV 3.5 (vs 5.5)
- 17/05/21 hand assisted laparoscopy. Nodal sampling (12a2). Non extrahepatic spread.
- **MULTIDISCIPLINARY EVALUATION: OLTX waiting list enrollment**
- 06/21 admission for cHolangiItIs; 29/06/2021 PTBD substitution; 01/07/21 left external PTBD substitution
- CT scan 05/08/21: SD

Ca 19.9 preOLTX 10.3



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

OLTx Mayo protocol

10/09/2021: OLTx (prot. MAYO); duration: 9h 35 min

Frozen sections: multiple biopsies of hepatic hilum and nodes -> no infiltration. Distal coledocus section -> negative

Classic technique, hepaticojejunostomy with ductoplasty for enlargement.

CIT 526 min (318 min hypotermic machine perfusion). WIT tot 43 min (partial wit 30 min)

HE: peri-hylar adenocarcinoma of extrahepatic biliary tree (i.e Klatskin tumor), perineural invasion, mucinous lakes with isolated neoplasm. 4 nodes (+frozen sections), negative. T2aN0M0, stage II

COMPLICATIONS:

- *E. Coli isolation from the wound (no antibiotic treatment)*
- *biliary fistula (conservative management)*
- X POD: abdominal pain -> CT scan: 4 small hypoperfusion areas (S6/S7, S3, S4b), small abdominal collections-> pericaval (40x25mm) and perihepatic (left lobus, 37x18mm)

Immunosuppression:

- induction: basilixamab;
- maintenance: tacrolimus (advagraf), everolimus

Discharge: XIII POD

Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

Follow up

- **10/12/2021 CT scan: negative**
- 08/02/22 abdomen MRI + T CT scan: negative (S5 11mm, benign)
- MGUS IGGk IGGlambda (3g/L), CMV and EBV reactivation (treated with Valganciclovir)-> follow up
- **03/2022 admission for colangytes**
- **from 06/2022 recurrent colangytes. Ca 19.9 17 (17/06/2022)**
- 09/2022 itching, biliary acid increasing (150) -> anticipation of the MRI
- **21-26/09/2022 admission for acute pancreatitis. Ca 19.9 10409**



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024


1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Follow up

- **13/09/2022 MRI with hepatospecific cm and colangio MRI:** absence of signal confluence right hepatic duct and of the left one, before the confluence without dilatation. **Dilatation of Wirsung duct and secondary ducts body-tail pancreas till the head.**
- **23/09/2022 CT scan with cm:** confirmation of dilatation of Wirsung (7mm istmus; 3-4mm head) sustained by suspected for neoplasm 10mm in periampullar region. **Suspected hepatic metastases (9mm S5 subglissonian; S7/S6/S5 10mm, 5mm)**
- **Repeated with thorax 29/09/2022: distal coledocous dilatation occupied by mass 12mm; adjacent suspected node**
 - **28/09/2022 EUS: 14mm hypoechoic mass, prepapillar region, clear boundaries, dilatation of Wirsung. FNB: pancreatic parenchyma with infiltration of moderate differentiated adenoca with mucinous aspects (MSS, pMMR)**
 - **10/2022 admission for cholangitis**



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma


21/11/2022: DCP

- Frozen sections: pancreatic and biliary section -> negative
- Demolition of the hepatic-jejunum anastomoses; Pancreatic-jejunum anastomosis (sec Blumgart) gastrojejunostomy Roux-Y; portal repair with peritoneal patch. Intra-Wirsung drainage.

HE: Ampullary mucinous adenocarcinoma (mucinous component 60%), intestinal differentiation, with ampullary adenomatous tubulo-villous component with high grade dysplasia. PanIN low grade. 18 negative nodes. **TNM T3b N0**, Stage IIB. KRAS mutated G12D

COMPLICATIONS:

3 POD abdominal pain -> CT scan: sub-hepatic collection 4 cm
Pancreatic fistula, antibiotic treatment, observation



Discharge: X POD

Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

Follow up

- 01/23 admission for abdominal pain after drainage washing; just observation and discharge
- 09/02/23 MRI with cm and colangiMRI: no recurrence**
- 02/2023 Ca 19.9 232 (in jenuary 54) -> repetition 03/07/23: 44 -> 05/10/2023: 161
- 08/04/23 CT scan: no recurrence
- Ca 19.9 03/07/23: 44
- 01/06/2023 CT scan: no recurrence
- 05/10/2023 CT scan: no recurrence
- 25/01/2024 oncological evaluation: no recurrence, continues follow up**

**Alive after 4 years,
 no recurrence**



di Lilina Golia
 15 set 2023 | 12:00
Il podista di Lumezzane ha subito un trapianto di fegato e lotta con un cancro al pancreas ma ha ripreso a correre



Patient Journey
 Approccio personalizzato al paziente e esperienze a confronto:
 Epatocarcinoma e Colangiocarcinoma

CONCLUSIONS

- MULTIDISCIPLINARITY
- HUB CENTER
- SPECIALIZED LIVER SURGEON AND
SPECIALIZED TEAM
- TRANSPLANT ONCOLOGY



Patient Journey

Approccio personalizzato al paziente e esperienze a confronto:
Epatocarcinoma e Colangiocarcinoma

01 Febbraio 2024

1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI VERONA